In-Med Prognostics L3C

Company profile

About In-Med Prognostics L3C

InMed Prognostics Inc. (InMed.AI) is a pioneer in AI-driven predictive analytics for precision neuroimaging, operating across India, Africa, the Middle East, and the USA. The company develops fully automated, organ-agnostic imaging platforms using multi-modal data including text, signal, and image analysis (US Patent No. 11263749). Their flagship product, NeuroShield MR Volumetry, is the world's first brain volumetry tool providing ethnicity-specific reference ranges adjusted to age, gender, and ethnicity, bringing precision medicine to neurodegenerative disease management. The platform has been rigorously validated with 280 subjects and cleared by the US FDA as a clinical decision-support tool. InMed's comprehensive product suite includes NeuroShield CT TBI for neurotrauma screening and quantification, NeuroFlo for neurology workflow optimization, and VivoShield Sports for whole-body MRI athletic wellness assessment. The company serves 220+ clinical sites worldwide with cloud-based solutions that are multi-scanner compatible and validated across 1.5T and 3T scanners from multiple manufacturers. Founded by Dr. Latha Poonamallee, InMed is expanding its portfolio into CT Brain applications, whole body MRI wellness solutions, and lesion detection for pancreatic and liver cancer. The company's mission is to make affordable, accessible healthcare tools available to everyone, everywhere, believing that investing in healthcare is investing in our collective human future.

Company description · In-Med Prognostics L3C official website